Transmitted drug resistance among HIV-1 drug-naïve patients in Greece

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3102589 60 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Transmitted drug resistance among HIV-1 drug-naïve patients in Greece
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives: Despite the success of antiretroviral treatment (ART), the persisting transmitted drug resistance (TDR) and HIV genetic heterogeneity affect the efficacy of treatment. This study explored the prevalence of TDR among ART-naïve HIV patients in Greece during the period 2016–2019. Methods: Genotypic resistance testing was available for 438 ART-naïve HIV patients. Multivariable Poisson regression models were fitted. Results: The majority of patients were male, and there was a slight predominance of Hellenic (26.5%) over non-Hellenic (21.9%) nationality. The prevalence of TDR was 7.8%. There was a predominance of mutations for non-nucleoside reverse-transcriptase inhibitors (5.7%) over nucleoside reverse-transcriptase inhibitors (0.2%). No mutations to protease inhibitors were detected. The prevalence of resistance was 22.1% based on all mutations identified through the HIVdb interpretation system. The most frequent resistance sites were E138A (9.6%), K103N (6.4%), and K101E (2.1%). The majority of detected mutations were confined to subtype A (52.6%), followed by B (19.6%). Non-Hellenic nationality was significantly associated with an increased risk of TDR (relative risk 1.32, 95% confidence interval 1.04–1.69). Conclusions: Non-B HIV infections predominate in Greece, with an increasing trend in recent years. The prevalence of TDR remains stable. Ongoing surveillance of resistance testing is needed to secure the long-term success of ART. © 2021 The Authors
Έτος δημοσίευσης:
2021
Συγγραφείς:
Kantzanou, M.
Karalexi, M.A.
Papachristou, H.
Vasilakis, A.
Rokka, C.
Katsoulidou, A.
Περιοδικό:
International Journal of Infectious Diseases
Εκδότης:
Elsevier B.V.
Τόμος:
105
Σελίδες:
42-48
Λέξεις-κλειδιά:
nonnucleoside reverse transcriptase inhibitor; RNA directed DNA polymerase inhibitor; anti human immunodeficiency virus agent, adult; antiretroviral therapy; antiviral resistance; Article; controlled study; DNA sequencing; drug tolerability; female; genetic heterogeneity; Greece; human; Human immunodeficiency virus 1 infection; Human immunodeficiency virus infected patient; Human immunodeficiency virus prevalence; infection risk; injection drug user; major clinical study; male; male homosexuality; men who have sex with men; risk factor; virus replication; virus transmission; drug effect; genetics; genotype; Human immunodeficiency virus 1; Human immunodeficiency virus infection; middle aged; mutation; prevalence; virology, Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; Greece; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Middle Aged; Mutation; Prevalence
Επίσημο URL (Εκδότης):
DOI:
10.1016/j.ijid.2021.02.043
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.